Skip to main content

Table 1 Description of study population and anti-hypertensive treatment of the groups

From: Unilateral adrenal hyperplasia is a usual cause of primary hyperaldosteronism. Results from a Swedish screening study

  Population
The rest of the screening population SPA-group
  All (n = 307) SP (n = 94) NSP (n = 213) All (n =46) SP (n = 28) NSP (n = 18)
Female 164 47 117 18 11 7
Male 189 75 114 28 7 21
Age (years) 60.0 ± 11.1 56.0 ± 11.9 61.8 ± 10.3 59.7 ± 10.6 56.3 ± 10.8 65.1 ± 7.9
BMI (kg/m 2 ) 28.7 ± 4.5 28.4 ± 5.2 28.8 ± 4.2 29.0 ± 4.2 28.6 ± 3.8 29.6 ± 4.7
Mean SBP (mmHg) 146.9 ± 21.0 149.9 ± 22.3 145.6 ± 20.4 152.0 ± 20.9 152.2 ± 20.9 152.7 ± 21.5
Mean DBP(mmHg 86.8 ± 10.6 87.5 ± 10.5 86.4 ± 10.7 91.0 ± 9.0 91.0 ± 8.1 90.9 ± 10.5
Duration of HT (years) 12.6 ± 9.8 13.1 ± 9.3 12.3 ± 10.1 12.9 ± 6.9 12.9 ± 5.6 12.8 ± 8.8
No of drugs* 1.8 ± 1.1 2.3 ± 1.3 1.6 ± 0.9 2.4 ± 1.1 2.6 ± 1.3 2.1 ± 0.8
No of drugs 0 to 3 279 75 204 39 21 18
No of drugs 4 to 5 26 18 8 7 7 0
β-blockers 165 60 105 34 22 12
ACE – & AII-inhibitors 154 60 94 24 16 8
diuretics 131 47 84 18 13 5
Spironolactone 0 0 0 2 2 0
Potassium supplements 14 8 6 3 3 0
Serum Potassium (mmol/l) 4.0 ± 0.4 3.9 ± 0.4 4.0 ± 0.4 3.7 ± 0.3 3.7 ± 0.5 3.7 ± 0.3
  1. The rest of the screening population (n = 307 = 353-46, i.e. the whole screening population – the SPA group) and the group suspected with primary hyperaldosteronism (the SPA group) due to the defined cut-off limits for serum aldosterone and serum aldosterone/renin ratio (ARR). SP = selected population. NSP = non-selected population. No of medicine = total number of antihypertensive drugs at the time of screening, presented as the mean value ± standard deviation. Respective antihypertensive drug is presented as total number of patients treated with it. β-blockers = β –receptor inhibitor. ACE = angiotensin converting enzyme. AII = angiotensin II. *Information on drugs is missing for 2 patients not being in the SPA-group.